• Profile
Close

A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis - Phase III clinical trial

Contemporary Clinical Trials Mar 16, 2018

Xue Y, et al. - The intention of experts was to determine the suitable dose of Ilaparazole in the treatment of reflux esophagitis. It was disclosed that the efficacy and safety of Ilaparazole (10 mg/day) in treating reflux esophagitis was similar to esomeprazole (40 mg/day). Findings displayed that Ilaparazole (10 mg/day) could be used in the treatment of esophagitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay